Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | See Remarks | September 08, 2023 | September 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date September 08, 2023 · Filed September 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2033-09-08 | Direct | 48,000 |
Reported balance
After 2023-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-08 · Grant · Acquired 48,000 · Balance 48,000 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2023 Filed Sep 12, 2023 20:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000275 · form4.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:10 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005254 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:15 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013869 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002890 · doc1.xml · derivative · entry 2 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F2 · derivative.exercise_date: 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002890 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:04 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001567619-20-020623 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 Preferred Stock · Derivative | 726 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · derivative · entry 7 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 Preferred Stock · Derivative | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · derivative · entry 6 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries A Preferred Stock · Derivative | 6,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · derivative · entry 5 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 6,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · nonDerivative · entry 4 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 1,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · nonDerivative · entry 3 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:56 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 6,835 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018004 · doc1.xml · nonDerivative · entry 2 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F2 · ownership.nature: Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.